Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

• Autor(a) principal: Parra, Rogerio S.
• Data de Publicação: 2019
• Outros Autores: Chebli, Julio M.F., Amarante, Heda M.B.S., Flores, Cristina, Parente, Jose M.L., Ramos, Odery, Fernandes, Milene, Rocha, Jose J.R., Feitosa, Marley R., Feres, Omar, Scotton, Antonio S., Nones, Rodrigo B., Lima, Murilo M., Zaltman, Cyrla, Goncalves, Carolina D., Guimaraes, Isabella M., Santana, Genoile O., Sassaki, Ligia Y. [UNESP], Hossne, Rogerio S. [UNESP], Bafutto, Mauro, Roberto, L. K., Faria, Mikaell A.G., Miszputen, Sender J., Gomes, Tarcia N.F., Catapani, Wilson R., Faria, Anderson A., Souza, Stella C.S., Caratin, Rosana F., Senra, Juliana T., Ferrari, Maria L.A.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.3748/wjg.v25.i38.5862; http://hdl.handle.net/11449/199521
• topic: Crohn's disease; Healthcare resources; Inflammatory bowel disease; Quality of life; Ulcerative colitis

Background: Inflammatory bowel diseases (IBD) have been associated with a low quality of life (QoL) and a negative impact on work productivity compared to the general population. Information about disease control, patient-reported outcomes (PROs), treatment patterns and use of healthcare resources is relevant to optimizing IBD management. Aim: To describe QoL and work productivity and activity impairment (WPAI), treatment patterns and use of healthcare resources among IBD patients in Brazil. Methods: A multicenter cross-sectional study included adult outpatients who were previously diagnosed with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC). At enrolment, active CD and UC were defined as having a Harvey Bradshaw Index ≥ 8 or a CD Activity Index ≥ 220 or calprotectin > 200 μg/g or previous colonoscopy results suggestive of inadequate control (per investigator criteria) and a 9-point partial Mayo score ≥ 5, respectively. The PRO assessment included the QoL questionnaires SF-36 and EQ-5D-5L, the Inflammatory Bowel Disease Questionnaire (IBDQ), and the WPAI questionnaire. Information about healthcare resources and treatment during the previous 3 years was collected from medical records. Chi-square, Fisher's exact and Student's t-/Mann-Whitney U tests were used to compare PROs, treatment patterns and the use of healthcare resources by disease activity (α = 0.05). Results: Of the 407 patients in this study (CD/UC: 64.9%/35.1%, mean age 42.9/45.9 years, 54.2%/56.6% female, 38.3%/37.1% employed), 44.7%/25.2% presented moderate-to-severe CD/UC activity, respectively, at baseline. Expressed in median values for CD/UC, respectively, the SF-36 physical component was 46.6/44.7 and the mental component was 45.2/44.2, the EQ-visual analog scale score was 80.0/70.0, and the IBDQ overall score was 164.0/165.0. Moderate to severe activity, female gender, being unemployed, a lower educational level and lower income were associated with lower QoL (P < 0.05). Median work productivity impairment was 20% and 5% for CD and UC patients, respectively, and activity impairment was 30%, the latter being higher among patients with moderate to severe disease activity compared to patients with mild or no disease activity (75.0% vs 10.0%, P < 0.001). For CD/UC patients, respectively, 25.4%/2.8% had at least one surgery, 38.3%/19.6% were hospitalized, and 70.7%/77.6% changed IBD treatment at least once during the last 3 years. The most common treatments at baseline were biologics (75.3%) and immunosuppressants (70.9%) for CD patients and 5-ASA compounds (77.5%) for UC patients. Conclusion: Moderate to severe IBD activity, especially among CD patients, is associated with a substantial impact on QoL, work productivity impairment and an increased number of IBD surgeries and hospitalizations in Brazil.